BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 15258698)

  • 1. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients.
    Urien S; Brain E; Bugat R; Pivot X; Lochon I; Van ML; Vauzelle F; Lokiec F
    Cancer Chemother Pharmacol; 2005 Jan; 55(1):55-60. PubMed ID: 15258698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of total and unbound plasma cisplatin in adult patients.
    Urien S; Lokiec F
    Br J Clin Pharmacol; 2004 Jun; 57(6):756-63. PubMed ID: 15151521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of cisplatin in adult cancer patients.
    de Jongh FE; Gallo JM; Shen M; Verweij J; Sparreboom A
    Cancer Chemother Pharmacol; 2004 Aug; 54(2):105-12. PubMed ID: 15127229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A simultaneous oral/intravenous population pharmacokinetic model for vinorelbine.
    Variol P; Nguyen L; Tranchand B; Puozzo C
    Eur J Clin Pharmacol; 2002 Oct; 58(7):467-76. PubMed ID: 12389069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis.
    Zhou H; Mayer PR; Wajdula J; Fatenejad S
    J Clin Pharmacol; 2004 Nov; 44(11):1235-43. PubMed ID: 15496641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetics of a HER2 tyrosine kinase inhibitor CP-724,714 in patients with advanced malignant HER2 positive solid tumors.
    Guo F; Letrent SP; Sharma A
    Cancer Chemother Pharmacol; 2007 Nov; 60(6):799-809. PubMed ID: 17285315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
    Meerum Terwogt JM; Groenewegen G; Pluim D; Maliepaard M; Tibben MM; Huisman A; ten Bokkel Huinink WW; Schot M; Welbank H; Voest EE; Beijnen JH; Schellens JM
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):201-10. PubMed ID: 11935212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values.
    Loos WJ; de Jongh FE; Sparreboom A; de Wit R; van Boven-van Zomeren DM; Stoter G; Nooter K; Verweij J
    J Clin Oncol; 2006 Apr; 24(10):1499-506. PubMed ID: 16574999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
    Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
    Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
    van den Bongard HJ; Mathôt RA; van Tellingen O; Schellens JH; Beijnen JH
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):16-24. PubMed ID: 12111107
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I dose-finding study and a pharmacokinetic/pharmacodynamic analysis of the neutropenic response of intravenous diflomotecan in patients with advanced malignant tumours.
    Trocòniz IF; Garrido MJ; Segura C; Cendrós JM; Principe P; Peraire C; Obach R
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):727-35. PubMed ID: 16261364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting.
    Nakade S; Ohno T; Kitagawa J; Hashimoto Y; Katayama M; Awata H; Kodama Y; Miyata Y
    Cancer Chemother Pharmacol; 2008 Dec; 63(1):75-83. PubMed ID: 18317761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric intravenous paracetamol (propacetamol) pharmacokinetics: a population analysis.
    Anderson BJ; Pons G; Autret-Leca E; Allegaert K; Boccard E
    Paediatr Anaesth; 2005 Apr; 15(4):282-92. PubMed ID: 15787918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and preliminary clinical data of the novel chemoprotectant BNP7787 and cisplatin and their metabolites.
    Verschraagen M; Boven E; Ruijter R; van der Born K; Berkhof J; Hausheer FH; van der Vijgh WJ
    Clin Pharmacol Ther; 2003 Aug; 74(2):157-69. PubMed ID: 12891226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circadian variability of pharmacokinetics of cisplatin in patients with non-small-cell lung carcinoma: analysis with the NONMEM program.
    Chen R; Li J; Hu WW; Wang ML; Zou SL; Miao LY
    Cancer Chemother Pharmacol; 2013 Nov; 72(5):1111-23. PubMed ID: 24061864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of oral busulfan in children.
    Schiltmeyer B; Klingebiel T; Schwab M; Mürdter TE; Ritter CA; Jenke A; Ehninger G; Gruhn B; Würthwein G; Boos J; Hempel G
    Cancer Chemother Pharmacol; 2003 Sep; 52(3):209-16. PubMed ID: 12811512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy.
    Panteix G; Beaujard A; Garbit F; Chaduiron-Faye C; Guillaumont M; Gilly F; Baltassat P; Bressolle F
    Anticancer Res; 2002; 22(2B):1329-36. PubMed ID: 12168946
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors affecting pharmacokinetic variability of oral topotecan: a population analysis.
    Léger F; Loos WJ; Fourcade J; Bugat R; Goffinet M; Mathijssen RH; Verweij J; Sparreboom A; Chatelut E
    Br J Cancer; 2004 Jan; 90(2):343-7. PubMed ID: 14735174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ropivacaine in neonates and infants: a population pharmacokinetic evaluation following single caudal block.
    Rapp HJ; Molnár V; Austin S; Krohn S; Gädeke V; Motsch J; Boos K; Williams DG; Gustafsson U; Huledal G; Larsson LE
    Paediatr Anaesth; 2004 Sep; 14(9):724-32. PubMed ID: 15330953
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Pharmacokinetic study of intraperitoneal chemotherapy with high-dose cisplatin for advanced ovarian cancer].
    Deng C; Huang R; Lian L
    Zhonghua Fu Chan Ke Za Zhi; 1996 Mar; 31(3):159-62. PubMed ID: 8758790
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.